Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression

Immunotherapy is an effective treatment in advanced non‐small cell lung cancer (NSCLC) patients with high PDL‐1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.[Image: see text]

Detalles Bibliográficos
Autores principales: Wong, Pui Yee, How, Soon Hin, Hassan, Radhiana, Abdul Azih, Muhammad Naimmuddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
REGULAR ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711218/
https://www.ncbi.nlm.nih.gov/pubmed/34964016
http://dx.doi.org/10.1002/agm2.12179
Descripción
Sumario:Immunotherapy is an effective treatment in advanced non‐small cell lung cancer (NSCLC) patients with high PDL‐1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.[Image: see text]

Ejemplares similares